

CITATION REPORT

List of articles citing

Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas

DOI: 10.1007/s00280-021-04274-6

Cancer Chemotherapy and Pharmacology, 2021, 88, 189-202.

Source: <https://exaly.com/paper-pdf/79977019/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
5	A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas. <i>Annals of Pharmacotherapy</i> , 2021 , 10600280211046298	2.9	1
4	Effect of food on capsule and granule formulations of selumetinib.. <i>Clinical and Translational Science</i> , 2022 ,	4.9	2
3	A Phase I, Open-label, Randomized, Crossover Study of the Relative Bioavailability of Capsule and Granule Formulations of Selumetinib.. <i>Clinical Therapeutics</i> , 2022 ,	3.5	
2	Physiologically Based Biopharmaceutics Model for Selumetinib Food Effect Investigation and Capsule Dissolution Safe Space [Part I: Adults.		1
1	Population pharmacokinetics of FCN-159, a MEK1/2 inhibitor, in adult patients with advanced melanoma and neurofibromatosis type 1 (NF1) and model informed dosing recommendations for NF1 pediatrics. 14,		0